Breaking News

Oncologie Receives Exclusive Navicixizumab License

To develop and commercialize navicixizumab in advanced heavily pretreated ovarian cancer

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Mereo BioPharma Group plc, and Oncologie, Inc. have entered a global license agreement for the development and commercialization of navicixizumab, an anti-DLL4/VEGF bispecific antibody currently being evaluated in a Phase Ib study in combination with paclitaxel in advanced heavily pretreated ovarian cancer. Navicixizumab previously completed a Phase 1a monotherapy study in patients with various types of refractory solid tumors and is one of two product candidates Mereo acquired through its 2019 ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters